
The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Perioperative Durvalumab in Gastric and Gastroesophageal …
Jun 1, 2025 · Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but …
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in …
Sep 15, 2024 · Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy …
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic ...
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, …
Parkinson’s Disease | NEJM - New England Journal of Medicine
Jul 31, 2024 · Parkinson’s disease is a multisystem neurodegenerative disorder with motor and prominent, sometimes premonitory, nonmotor symptoms. Detection of gene variants may …
Asundexian versus Apixaban in Patients with Atrial Fibrillation | NEJM
Sep 1, 2024 · Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor XI …
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe …
Oct 28, 2024 · For patients with asymptomatic severe aortic stenosis and preserved left ventricular ejection fraction, current guidelines recommend routine clinical surveillance every 6 …
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma …
Oct 16, 2024 · Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin’s lymphoma improves outcomes in adult and pediatric patients. However, …
Antibiotic Treatment for 7 versus 14 Days in Patients with …
Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …
Daratumumab or Active Monitoring for High-Risk Smoldering …
Dec 9, 2024 · Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high …